
|Articles|May 17, 2008
Skinvisible signs licensing agreement for two acne products
Las Vegas - Skinvisible, a research and development company focused on dermatology products, has signed a licensing agreement with Embil Pharmaceutical Co. for the right to develop and market two acne products, Earthtimes.org reports.
Advertisement
Las Vegas
- Skinvisible, a research and development company focused on dermatology products, has signed a licensing agreement with Embil Pharmaceutical Co. for the right to develop and market two acne products, Earthtimes.org reports.
The two prescription anti-acne products are formulated with Invisicare,a patented polymer delivery technology, with the active ingredients Clindamycin HCL and Retinoic Acid.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Novel Botanical Moisturizer Demonstrates Superior Efficacy Over Metronidazole in Phase 2 Rosacea Trial
2
The Emerging Role of Oral Peptide Therapeutics in Dermatology
3
New Immune-Mediated Therapies in AD, Alopecia Areata, and HS Presented at SDNP
4
Translational Takeaways: June 7, 2026
5














